Tevard Biosciences is developing novel gene therapy platforms to target Dravet Syndrome and other rare diseases with high unmet need. The company was founded in 2017 by Daniel Fischer and Warren Lammert, two parents of girls with Dravet Syndrome, and Harvey Lodish. Tevard’s SAB includes Bob Langer, David Liu, Lita Nelsen, Orrin Devinsky, and Ann Poduri.